Better treatment for grade-three and grade-four gliomas

Better treatment for grade-three and grade-four gliomas

Posted 17 December, 2021 at 08:57

Author Jessica McClory on behalf of In Sues Name


Researchers at the Indian Institute of Science (IISc) have identified blood-based biomarkers that could help predict the progression and survival time in patients with late-stage brain tumours.

The discovery could help in better treatment of grade-three and grade-four gliomas which are usually associated with poor prognosis.

Researchers from the Centre for BioSystems Science and Engineering (BSSE) at IISc, and the Mazumdar Shaw Centre for Translational Research and Mazumdar Shaw Medical Foundation analysed blood samples from individuals with gliomas to identify surface proteins on immune cells in the blood whose levels were closely linked to tumour progression.

The results have been published in OncoImmunology,  under the title of ‘Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin’

More from In Sues Name

New cancer treatment making headway
Press Release

New cancer treatment making headway

21 May 2022
Stronger treatments for glioblastoma
Press Release

Stronger treatments for glioblastoma

18 May 2022
Join our Golf Day this June!
Press Release

Join our Golf Day this June!

16 May 2022
More accurate diagnosis on the horizon...
Press Release

More accurate diagnosis on the horizon...

09 May 2022
Card image cap
user

In Sues Name

Charity

Profile Feed
In Sue’s Name was founded in 2014 by David Taylor in memory of his beloved daughter Sue Blasotta, who died in 2011 of brain tumours. Sue was devoted to her husband Joe and their children Sasha and Daniel. She adored her career, first in recruitment with Reed Employment and then caring for ch...

59

Press Releases